Rosetta Genomics Ltd. (USA)(NASDAQ:ROSG) announced the earnings results for Fiscal Year 2016 and Q2. The results came in during After-hours on Sep 26, 2016. Company reported revenue of $2.41M. Analysts estimated a revenue of $3.01M. Earnings per share were $-0.15. Analysts had estimated an EPS of $-0.17.
Rosetta Genomics Ltd. (USA) (ROSG) shares turned negative on Thursdays trading session with the shares closing down -0.0051 points or -0.56% at a volume of 68,015. The pessimistic mood was evident in the company shares which never went considerably beyond the level of $0.93. The peak price level was also seen at $0.93 while the days lowest was $0.8958. Finally the shares closed at $0.9099. The 52-week high of the shares is $3.1 while the 52-week low is $0.71. According to the latest information available, the market cap of the company is $19 M.
Rosetta Genomics Ltd. is a molecular diagnostics company advancing microRNA-based diagnostics discovered and developed through its microRNAs and platform technologies. The Company has developed platform technologies for the identification extraction quantification and analysis of microRNAs from a range of sample types. These technologies enable the identification and advancement of multiple diagnostic projects in cancer cardiovascular diseases and other indications. The Company’s four commercial oncology tests have been launched in multiple countries across the world. The Company is working to develop additional tests in the cancer realm and in other fields. It is marketing and selling the four diagnostic tests based on its microRNA technologies which include Rosetta Cancer Origin Test Rosetta Lung Cancer Test Rosetta Kidney Cancer Test and Rosetta Mesothelioma Test. The Company’s therapeutic pipeline consists of the projects such as CMV Therapeutic and Rimonim Consortium.